Med24
diabetes 22. 9. 2026 • 1 min read • U.S. Food and Drug Administration (OpenFDA)

Dorzolamide Hydrochloride And Timolol Maleate Dorzolamide Hy: FDA Clinical Pharmacology, Indications and Prescribing Update

1 INDICATIONS AND USAGE Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5% (preservative free) is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/0.5% (preservative free) is indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. This solution combines dorzolamide hydrochloride, an inhibitor of human carbonic anhydrase II, with timolol maleate, a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent. Both components reduce IOP by decreasing aqueous humor secretion.

Sponsored content

Key Clinical Findings

The IOP-lowering effect of the solution administered twice daily was less than that of timolol administered twice daily and dorzolamide administered three times daily. The IOP lowering effect of the solution was approximately 1 mmHg less than that of concomitant therapy with dorzolamide administered three times daily and timolol twice daily. The solution’s IOP-lowering effect was consistent during a 12-month follow-up period.

Original Scientific Source
U.S. Food and Drug Administration (OpenFDA)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement